Ob/Gyn Medical News about osteoporosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Amgen to collaborate with GSK to commercialize denosumab in Europe for postmenopausal osteoporosis
GlaxoSmithKline, 08/05/09

Amgen and GlaxoSmithKline announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize the drug for PMO and oncology in the United States and Canada and for all oncology indications in Europe and specified markets.

<< Previous
Hysteroscopic Myomectomy and Case Volume Hysteroscopic Myomectomy...

Next >>
Late Postpartum Hemorrhage After Hemostatic Square Suturing...